Abstract
(Abstracted from Genet Med 2021;23:1847–1853) In 2015, a study found that traditional cell-free DNA (cfDNA) screening had the capability to detect approximately 70% to 80% of the karyotypic abnormalities identified in fetuses and infants. The remaining 20% to 30% that are missed include clinically relevant findings such as subchromosomal deletions and duplications, rare autosomal aneuploidies, and polyploidy, representing an area of growth for prenatal screening tests, and genome-wide cfDNA screening is now available.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
